MINI FUTURE LONG - GILEAD SCIENCES | Real-time Boerse Frankfurt Warrants 09:20:56 01/07/2024 BST | ||
| 1.45 EUR | -0.68% |
|
| 1 month | +41.75% | ||
| 3 months | -26.63% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 01/07/24 | 1.45 | -0.68% |
| 28/06/24 | 1.46 | -3.31% |
| 27/06/24 | 1.51 | -4.43% |
| 26/06/24 | 1.58 | -0.63% |
| 25/06/24 | 1.59 | -9.14% |
Real-time Boerse Frankfurt Warrants
Last update July 01, 2024 at 09:20 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PN1URB |
| ISIN | DE000PN1URB3 |
| Date issued | 31/07/2020 |
| Strike | 52.73 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.11 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.84 € |
|---|---|
| Lowest since issue | 0.7 € |
| Spread | 0.03 € |
| Spread % | 2.03% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
68.61
USD
Average target price
82.97
USD
Spread / Average Target
+20.93%
- Stock Market
- Certificates
- Certificat
